GlaxoSmithKline is partnering with German-based clinical-stage biotech Immatics Biotechnologies to develop novel adoptive cell therapies targeting multiple cancer indications.
The companies will collaborate on the identification, research and development of next-generation T-Cell Receptor Therapeutics with a focus on solid tumors. The partners will initially develop autologous T-cell therapies with the option to add allogeneic cell therapies using Immatics’ proprietary ACTallo approach.
With the deal, Immatics will receive an upfront payment of ~$50 million for two initial programs and is eligible to receive over $550M in development, regulatory and commercial milestone payments.
Read the press release
